A scientific study conducted by researchers at the University of “Catolica” in Rome, in collaboration with the Italian University of Rome, said that the discovery of a new important key within the cells could pave the way for the development of innovative treatments for a group of diseases, including Parkinson disease and some rare diseases associated with lack of mitchondria. The study indicated that this key is an enzyme known as “phosphatase B55” or (PP2A-B55Alpha), which is an essential component of the control of mitochondria balance (power plants) in the cell. The researchers concluded that reducing the activity of this enzyme in a pilot model of Parkinson disease has led to reducing the kinetic symptoms of the disease, pointing out that these results can open the way for the development of new medicines aimed at this important path for Parkinson’s treatment and other disorders. The study published in the Scientific Progress Journal of Professor Francesco Chikikon, Professor of Biochemistry at the Department of PI Technological Sciences at the University of Catolica, with the participation of Dr. Valentina Chanvanelli, a participating professor at the University of Rome, and Agostino Gemili, the most important researcher to the “young researchers”. A scientific background. Metochondria is one of the most important organs needed for cells to survive, as the energy needed for its work is produced, and its defect is a major cause in various diseases, including Parkinson and rare mitochondria diseases that affect the muscles, eyes or brain. The study showed that an accurate balance within the cells must be preserved between disposing of damaged mitochondria and replacement with new, but in some diseases this balance is disturbed, or the cells lose an excessive number of mitochondria or the accumulation of damaged members, which threatens the survival of the cell itself. In the case of Parkinson’s disease in particular, the loss of mitochondria contributes to the death of neurons producing dopamine, a process that is the basis of the disease. The details of the study confirmed that this enzyme represents an important component of controlling the process of balance of mitochondria as it improves the “Metophaji” process, which is the mechanism that enables the removal of damaged and dangerous mitochondria. On the other hand, it stabilizes the basic components of the new Metochondria formation process, which maintains a dynamic balance between removal and renewal. Professor Francesco Chikkouni said that the importance of this discovery is that the effects of that enzyme are directly related to the “Parkan” protein, a central protein in mitophagy mechanisms and directly related to Parkinson disease. The researchers added that when they applied the techniques to reduce the B55 enzyme levels in fruit flies, a model used to study Parkinson disease, a remarkable improvement in motor symptoms as well as in the mitochuric changes associated with the disease, which emphasizes that this effect needs the presence of a barren protein. The study warned that the future idea lies in the development of small pharmaceutical particles that can enter the brain and reach the neurons that produce dopamine and then reduce their death. Professor Chicouni emphasized that this approach in the future could develop a comprehensive drug that can adapt the work of the B55 enzyme to treat different mitochondrical diseases, such as some diseases of mitochondria or neurological neurological diseases. The study also warned that the imbalance in the number and quality of the mitochondria plays a significant role in the power of cancer cells to adapt and resist treatments, and that the control of the B55 activity can open the way for new therapeutic approaches in the field of crops. The research team emphasized that the future goal is to define safe molecules and treatment strategies that enable the B55 enzyme activity within pre -clinical models, as well as in human cell models focusing on studying the impact of this amendment to other neurological and degenerative diseases that are linked to mitochondria. New treatment prospects, and the study believed that these results are a promising step towards opening new horizons to understand the mechanisms of Parkinson and mitochuric diseases and the possibility of converting this concept into concrete treatment interventions. The results indicated that the combination of mettophage and the formation of a new metochondria in a balanced way is the key to maintaining the health of the cell and that the B55 represents the central checkpoint in this process. The researchers reported that the loss of balance in this process could be a common cause between neurological diseases such as Parkinson and rare diseases affecting muscle, eyes or brain. The study emphasized that these scientific progress would not be made without cooperation between academic research institutions and medical centers, reflecting the importance of multidisciplinary work to face major health challenges. The results emphasized that achieving an effective treatment for Parkinson disease and other diseases associated with mitochondria can be closer to what some people think if the researchers succeed in developing the medicine instruments needed to control this enzyme. The researchers said they would continue to investigate the relationship between the B55 and the Barkin protein to build a solid scientific basis that enabled the development of accurate treatments that threaten the neurons with death. The study pointed out that these efforts represent the beginning of a long way to new treatments, but it provides concrete hope for millions of patients with Parkinson and other intricate diseases. The researchers further said that the next challenge would be to prove the effectiveness and safety of these strategies in human models before moving to clinical trials. The research team noted that future development could also include cancer treatment applications by undermining the capacity of cancer cells to adjust their mitochondria to withstand treatment. The results indicated that the control of the B55 could open the way for comprehensive treatment strategies that can open not only neurological and degenerative diseases, but also rare diseases and even some forms of crops. The researchers added that they are optimistic that the current results will push the medical research community to investigate more about the role of mitochondria in health and diseases. They emphasized that success in this area can radically change the way in which we understand the diseases of nervous degeneration and mitochuric diseases and perhaps even cancer. The study concluded that the road is still long, but that the current discoveries are a good basis for building a new therapeutic future based on a deeper understanding of the dynamics of Mitochondria and its role in cell survival.
A study reveals an ‘important key’ that can revolutionize Parkinson’s disease
